A
0.231
0.00 (-0.43%)
| Penutupan Terdahulu | 0.232 |
| Buka | 0.241 |
| Jumlah Dagangan | 458,448 |
| Purata Dagangan (3B) | 7,641,239 |
| Modal Pasaran | 11,522,925 |
| Julat 52 Minggu |
| EPS Cair (TTM) | 303.08 |
| Nisbah Semasa (MRQ) | 1.43 |
| Aliran Tunai Operasi (OCF TTM) | -19.60 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -15.17 M |
| Pulangan Atas Aset (ROA TTM) | -158.88% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | AEON Biopharma, Inc. | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 1.9 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 0.0 |
| Penilaian Relatif | NA |
| Kesihatan Kewangan | -3.5 |
| Persekitaran Makro | -2.8 |
| AI Insight | NA |
| AI Technical | NA |
| Purata | -0.03 |
|
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed a Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine. AEON Biopharma, Inc. is based in Irvine, California. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 24.46% |
| % Dimiliki oleh Institusi | 14.66% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Beacon Wealthcare Llc | 30 Sep 2026 | 12,856 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |